1Owen, MJ, Sawa, A, Mortensen, PB. Schizophrenia. Lancet 2016; 388: 86–97.
2Hor, K, Taylor, M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24 (4 suppl): 81–90.
3Tiihonen, J, Lonnqvist, J, Wahlbeck, K, Klaukka, T, Niskanen, L, Tanskanen, A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620–7.
4Copeland, LA, Mortensen, EM, Zeber, JE, Pugh, MJ, Restrepo, MI, Dalack, GW. Pulmonary disease among inpatient decedents: impact of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 720–6.
5Walker, AM, Lanza, LL, Arellano, F, Rothman, KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671–7.
6Hung, GC, Liu, HC, Yang, SY, Pan, CH, Liao, YT, Chen, CC, et al. Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study. J Clin Psychiatry 2016; 77: 60–6.
7Leung, JG, Hasassri, ME, Barreto, JN, Nelson, S, Morgan, RJ 3rd. Characterization of admission types in medically hospitalized patients prescribed clozapine. Psychosomatics 2017; 58: 164–72.
8Stoecker, ZR, George, WT, O'Brien, JB, Jancik, J, Colon, E, Rasimas, JJ. Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol 2017; 32: 155–60.
9Kuo, CJ, Yang, SY, Liao, YT, Chen, WJ, Lee, WC, Shau, WY, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013; 39: 648–57.
10Mustafa, FA, Burke, JG, Abukmeil, SS, Scanlon, JJ, Cox, M. ‘Schizophrenia past clozapine’: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry 2015; 48: 11–4.
11Taylor, DM, Douglas-Hall, P, Olofinjana, B, Whiskey, E, Thomas, A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry 2009; 194: 165–7.
12Abdelmawla, N, Ahmed, MI. Clozapine and risk of pneumonia. Br J Psychiatry 2009; 194: 468–9.
13Bello, S, Menendez, R, Torres, A, Reyes, S, Zalacain, R, Capelastegui, A, et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest 2014; 146: 1029–37.
14Jolles, S, Borrell, R, Zouwail, S, Heaps, A, Sharp, H, Moody, M, et al. Calculated globulin (CG) as a screening test for antibody deficiency. Clin Exp Immunol 2014; 177: 671–8.
15Jolles, S. The variable in common variable immunodeficiency: a disease of complex phenotypes. J. Allergy Clin Immunol Pract 2013; 1: 545–56.
16Milford, W. A., Joanna, S., Rowbottom, A, Wild, GD. Handbook of Clinical Immunochemistry (9th edn). PRU Publications, 2007.
18Chua, I, Lagos, M, Charalambous, BM, Workman, S, Chee, R, Grimbacher, B. Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG. J Allergy Clin Immunol 2011; 127: 1410–1.
19Meltzer, HY, Alphs, L, Green, AI, Altamura, AC, Anand, R, Bertoldi, A, et al. Clozapine treatment for suicidality in schizophrenia: international Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82–91.
20National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Prevention and Management.NICE, 2014.
21van Vollenhoven, RF, Emery, P, Bingham, CO 3rd, Keystone, EC, Fleischmann, RM, Furst, DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72: 1496–502.
22Christou, EAA, Giardino, G, Worth, A, Ladomenou, F. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. Int Rev Immunol 2017; 36: 352–9.
23Resnick, ES, Moshier, EL, Godbold, JH, Cunningham-Rundles, C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood 2012; 119: 1650–7.
24McMillan, SA, Douglas, JP, Archbold, GP, McCrum, EE, Evans, AE. Effect of low to moderate levels of smoking and alcohol consumption on serum immunoglobulin concentrations. J Clin Pathol 1997; 50: 819–22.
25Kelly, C, McCreadie, RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999; 156: 1751–7.
26Roge, R, Moller, BK, Andersen, CR, Correll, CU, Nielsen, J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res 2012; 140: 204–13.
27Alvir, JM, Lieberman, JA, Safferman, AZ, Schwimmer, JL, Schaaf, JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7.
28Lozano, R, Marin, R, Santacruz, MJ, Pascual, A. Selective immunoglobulin M deficiency among clozapine-treated patients: a nested case-control study. Prim Care Companion CNS Disord 2015; 17: 10.4088/PCC.
29Jolles, S, Chapel, H, Litzman, J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency - a practical approach. Clin Exp Immunol 2016; 188: 333–41.